ELI LILLY & Co LLY

Currently 3 bullish, 0 bearish — stable.

Analysts are holding steady at 3 bullish to 0 bearish.

3 YouTube analysts cover ELI LILLY & Co (LLY).

3 analysts have covered LLY so far…

Analyst opinions

InvestAnswers15d ago

Business note$LLYSwingNarrative

AI-biotech momentum is drawing fresh attention after doing well.

Lily's AI-biotech narrative has attracted momentum, with the stock described as doing well as investors jump on the bandwagon.

The segment links Lily's recent strength to investors “jumping on” an AI biotech bandwagon. That makes the move more sentiment- and narrative-driven, so the main risk is a fast reversal if the theme cools or catalysts disappoint.

Publish-day $1144.68 · 06/09

"📈 Crazy new Bottom Signal? ARMA 20-Yr Lockup, AI Fire & Scarcity update 🥇"

Passive Income Investing49d ago

BULL$LLY

productive options fit for BIGY fund

LLY was added to BIGY as an option-writing candidate (weekly options available) because it also screened as sufficiently “productive” for covered call premium generation and diversification.

LLY qualified for BIGY on dual criteria: available weekly options and sufficient covered-call premium productivity. The addition broadens sector exposure within the fund while keeping its income-generation targets on track.

Publish-day $987.05 · 05/06

"BIGY Dividend SAFE? | Full Q&A Evolve ETFs: BANK UTES QQQY LIFE ETFs Discussed"

Passive Income Investing80d ago

BULL$LLY

pharma franchise anchors defensive layer

I view Eli Lilly as a defensive/high‑quality pharmaceutical holding in the fund’s defensive layer due to its major pharma franchise.

Eli Lilly's major pharmaceutical franchise provides high-quality defensive characteristics within the fund's defensive sleeve. Its established drug portfolio supports non-cyclical revenue suitable for portfolio stability.

Publish-day $935.58 · 04/05

"NEW Brompton PAYG ETF: 20% Yield + Global Diversification = Best NEW Covered Call ETF?"

No official filings surfaced for LLY yet.